Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting

Current Diabetes Reports

Volumn 17, Issue 8, 2017, Pages

  Seggelke, Stacey A ^a   Lindsay, Mark C ^a   Hazlett, Ingrid ^a   Sanagorski, Rebecca ^a   Eckel, Robert H ^a   Low Wang, Cecilia C ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular; Diabetes; Hospital; Hyperglycemia; Inpatient; Insulin

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DULAGLUTIDE; EMPAGLIFLOZIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; LINAGLIPTIN; LIXISENATIDE; METFORMIN; NATEGLINIDE; PLACEBO; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DRUG APPROVAL; DRUG SAFETY; DRUG WITHDRAWAL; GLYCEMIC CONTROL; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LACTIC ACIDOSIS; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNSTABLE ANGINA PECTORIS; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG EFFECTS; HOSPITAL; RISK FACTOR;

CARDIOVASCULAR SYSTEM; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HOSPITALS; HUMANS; HYPOGLYCEMIC AGENTS; RISK FACTORS;

EID: 85023746021     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-017-0884-1     Document Type: Review

References (85)

1. Umpierrez G, Hellman R, Korytkowski M, Kosiborod M, Maynard G, Montori V, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:16–38. doi:10.1210/jc.2011-2098.
2. American Diabetes Association. 14. Diabetes care in the hospital. Diabetes Care. 2017;40:S120–7. doi:10.2337/dc17-S017.
3. Low Wang C, Hess C, Hiatt W, Goldfine A. Clinical update: cardiovascular disease in diabetes mellitus. Circulation. 2016;2016(133):2459–502. doi:10.1161/CIRCULATIONAHA.116.022194.
4. Ferrannini E, DeFronzo R. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36:2288–96. doi:10.1093/eurheartj/ehv239.
5. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, et al. American Associaton of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–31. doi:10.2337/dc09-9029.
6. Rackley C, Russel R, Rogers W, Mantle J, McDaniel H, Papapietro S. Clinical experience with glucose-insulin-potassium therapy in acute myocardial infarction. Am Heart J. 1981;102:1038–49.
7. Clark R, English M, McNeill G, Newton R. Effect of intravenous infusion of insulin in diabetics with acute myocardial infarction. Br Med J. 1985;291:303–5.
8. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26(1):57–65.
9. Malmberg K, Rydén L, Hamsten A, Herlitz J, Waldenström A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes insulin-glucose in acute myocardial infarction. Eur Heart J. 1996;17(9):1337–44.
10. Ritsinger V, Malmberg K, Mårtensson A, Rydén L, Wedel H, Norhammar A. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised diabetes mellitus insulin glucose infusion in acute myocardial infarction (DIGAMI 1) trial. Lancet Diabetes Endocrinol. 2014;2(8):627–33. doi:10.1016/S2213-8587(14)70088-9.
11. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1359–67.
12. Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2003;125(5):1007–21.
13. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283–97. doi:10.1056/NEJMoa0810625.
14. de Mulder M, Umans VA, Cornel JH, van der Zant FM, Stam F, Oemrawsingh RM, et al. Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial. JAMA Intern Med. 2013;173(20):1896–904. doi:10.1001/jamainternmed.2013.10074.
15. Mellbin LG, Malmberg K, Waldenström A, Wedel H, Rydén L, DIGAMI 2 investigators. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial. Heart. 2009;95(9):721–7. doi:10.1136/hrt.2008.152835.
16. Study Investigators NICE-SUGAR, Finfer S, Liu B, Chittock DR, Norton R, Myburgh JA, et al. Hypoglycemia and risk of death in critically ill patients. N Engl J Med. 2012;367(12):1108–18. doi:10.1056/NEJMoa1204942.
17. Lowden E, Schmidt K, Mulla I, Andrei AC, Cashy J, Oakes DJ, et al. Evaluation of outcomes and complications in patients who experience hypoglycemia after cardiac surgery. Endocr Pract. 2017;23(1):46–55. doi:10.4158/EP161427.OR.
18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89. doi:10.1056/NEJMoa0806470.
19. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
20. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–65.
21. Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebovitz H, et al., American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2002;25:S28–32.
22. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32:1900–8. doi:10.1093/eurheartj/ehr077.
23. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;68:2070–80. doi:10.1001/archinte.168.19.2070.
24. Kooy A, de Jager J, Lehert P, Bets D, Wulffelé MG, Donker AJ, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169(6):616–25. doi:10.1001/archinternmed.2009.20.
25. Sullivan D, Forder P, Simes J, Whiting M, Kritharides L, Merrifield A, et al., FIELD Study Investigators. Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study. Diabetes Res Clin Pract. 2011;94(2):284–90. doi:10.1016/j.diabres.2011.07.028.
26. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6(3):395–402. doi:10.1161/CIRCHEARTFAILURE.112.000162.
27. DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism. 2016;65(2):20–9. doi:10.1016/j.metabol.2015.10.014.
28. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–75. doi:10.1001/jama.2014.15298.
29. Cucchiari D, Podestà MA, Merizzoli E, Calvetta A, Morenghi E, Angelini C, et al. Dose-related effects of metformin on acid-base balance and renal function in patients with diabetes who develop acute renal failure: a cross-sectional study. Acta Diabetol. 2016;53(4):551–8. doi:10.1007/s00592-016-0836-2.
30. Ozeki T, Kawato R, Watanabe M, Minatoguchi S, Murai Y, Ryuge A, et al. A fatal case of metformin-associated lactic acidosis. Intern Med. 2016;55(7):775–8. doi:10.2169/internalmedicine.55.5415.
31. FDA. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. Accessed 6 Jan 2017.
32. Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus (Review). Cochrane Database of Systematic Reviews. 2016;10:CD012151. doi:10.1002/14651858.CD012151.pub2.
33. Huang Y, Abdelmoneim AS, Light P, Qiu W, Simpson SH. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. J Diabetes Complicat. 2015;29(2):196–202. doi:10.1016/j.jdiacomp.2014.11.012.
34. Connelly KA, Yan AT, Leiter LA, Bhatt DL, Verma S. Cardiovascular implications of hypoglycemia in diabetes mellitus. Circulation. 2015;132:2345–50. doi:10.1161/CIRCULATIONAHA.115.015946.
35. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care. 2011;34:S132–7. doi:10.2337/dc11-s220.
36. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24:2943–52. doi:10.1185/03007990802418851.
37. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al., SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26. doi:10.1056/NEJMoa1307684.
38. White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, et al. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011;162(4):620–6. doi:10.1016/j.ahj.2011.08.004.
39. Cornel JH, Bakris GL, Stevens SR, Alvarsson M, Bax WA, Chuang LM, et al., TECOS Study Group. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. Diabetes Care. 2016;39(12):2304–10. doi:10.2337/dc16-1415.
40. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR - TIMI 53 randomized trial. Circulation. 2014;130(18):1579–88. doi:10.1161/CIRCULATIONAHA.114.010389.
41. Rehman MB, Tudrej BV, Soustre J, Buisson M, Archambault P, Pouchain D, et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab. 2016:S1262–3636. doi:10.1016/j.diabet.2016.09.005.
42. • Mannucci E, Monami M. Cardiovascular safety of incretin-based therapies in type 2 diabetes: systematic review of integrated analyses and randomized controlled trials. Adv Ther. 2017;34(1):1–40. doi:10.1007/s12325-016-0432-4. This is a recent meta-analysis of the CV safety of two classes of antidiabetic drugs with low risk for hypoglycemia in the outpatient setting and may play a potential role in hospitalized patients
43. Coch RW, Green JB. Current cardiovascular outcomes trials in type 2 diabetes: perspectives and insight. Nutr Metab Cardiovasc Dis. 2016;26(9):767–72. doi:10.1016/j.numecd.2016.06.004.
44. FDA. FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. http://www.fda.gov/Drugs/DrugSafety/ucm486096.htm. Retrieved December 24,2016.
45. Bethel MA, Engel SS, Green JB, Huang Z, Josse RG, Kaufman KD, et al., TECOS Study Group. Assessing the safety of sitagliptin in older participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS). Diabetes Care. 2017; doi:10.2337/dc16-1135.
46. Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, et al. Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Intern Med. 2016;176(10):1464–73. doi:10.1001/jamainternmed.2016.1522.
47. De La Rosa GC, Donado JH, Restrepo AH, Quintero AM, González LG, Saldarriaga NE, et al., Grupo de Investigacion en Cuidado intensivo: GICI-HPTU. Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial. Crit Care. 2008;12(5):R120. doi:10.1186/cc7017.
48. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al., German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2009;358(2):125–39. doi:10.1056/NEJMoa070716.
49. Preiser JC, Devos P, Ruiz-Santana S, Mélot C, Annane D, Groeneveld J, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med. 2009;35(10):1738–48. doi:10.1007/s00134-009-1585-2.
50. Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care. 2006;29(4):765–70. doi:10.2337/diacare.29.04.06.dc05-1894.
51. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354(5):449–61. doi:10.1056/NEJMoa052521.
52. Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al., DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26(7):650–61. doi:10.1093/eurheartj/ehi199.
53. Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007;30(9):2181–6. doi:10.2337/dc07-0295.
54. Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011;34(2):256–61. doi:10.2337/dc10-1407.
55. Umpierrez GE, Smiley D, Hermayer K, Khan A, Olson DE, Newton C, et al. Randomized study comparing a basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. Diabetes Care. 2013;36(8):2169–74. doi:10.2337/dc12-1988.
56. Deusenberry CM, Coley KC, Korytkowski MT, Donihi AC. Hypoglycemia in hospitalized patients treated with sulfonylureas. Pharmacotherapy. 2012;32(7):613–7. doi:10.1002/j.1875-9114.2011.01088.
57. •• Pasquel FJ, Gianchandani R, Rubin DJ, Dungan KM, Anzola I, Gomez PC, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2016;S2213-8587(16):30402–8. doi:10.1016/S2213-8587(16)30402-82016:8587(16): 30402-30408. This multicenter randomized controlled trial of a newer oral agent with low risk for hypoglycemia and a potential role in hospitalized patients is a model for future collaborative multicenter inpatient clinical trials in diabetes
58. Umpierrez GE, Gianchandani R, Smiley D, Jacobs S, Wesorick DH, Newton C, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes. Diabetes Care. 2013;36(11):3430–5. doi:10.2337/dc13-0277.
59. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3(2):195–201. doi:10.1161/CIRCIMAGING.109.899377.
60. Abuannadi M, Kosiborod M, Riggs L, House JA, Hamburg MS, Kennedy KF, et al. Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. Endocr Pract. 2013;19(1):81–90. doi:10.4158/EP12196.OR.
61. Lønborg J, Kelbæk H, Vejlstrup N, Bøtker HE, Kim WY, Holmvang L, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv. 2012;5:288–95. doi:10.1161/CIRCINTERVENTIONS.112.968388.
62. Mecott GA, Herndon DN, Kulp GA, Brooks NC, Al-Mousawi AM, Kraft R, et al. The use of exenatide in severely burned pediatric patients. Crit Care. 2010;14(4):R153. doi:10.1186/cc9222.
63. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al., LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. doi:10.1056/NEJMoa1603827.
64. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al., SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. doi:10.1056/NEJMoa1607141.
65. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al., ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57. doi:10.1056/NEJMoa1509225.
66. Monami M, Cremasco F, Lamanna C, Colombi C, Desideri CM, Iacomelli I, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res. 2011;2011:215764. doi:10.1155/2011/215764.
67. Ratner R, Han J, Nicewarmer D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011;10:22–32. doi:10.1186/1475-2840-10-22.
68. Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS, et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol. 2013;33(9):2252–60. doi:10.1161/ATVBAHA.113.301586.
69. Chen WR, Shen XQ, Zhang Y, Chen YD, Hu SY, Qian G, et al. Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine. 2016;52(3):516–26. doi:10.1007/s12020-015-0798-0.
70. Nozue T, Yamada M, Tsunoda T, Katoh H, Ito S, Iwaki T, et al. Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Heart Vessel. 2016;31(8):1239–46. doi:10.1007/s00380-015-0734-5.
71. van Raalte DH, van Genugten RE, Linssen MM, Ouwens DM, Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced intolerance and islet-cell dysfunction in humans. Diabetes Care. 2011;34(2):412–7. doi:10.2337/dc10-1677.
72. Ranta F, Avram D, Berchtold S, Dufer M, Drews G, Lang F, et al. Dexamethasone induces cell death in insulin secreting cells, an effect reversed by exendin-4. Diabetes. 2006;55:1380–90. doi:10.2337/db05-1220.
73. Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care. 2009;13(3):R67. doi:10.1186/cc7874.
74. Funch D, Gydesen H, Tornøe K, Major-Pedersen A, Chan KA. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other anti-diabetic drugs. Diabetes Obes Metab. 2014;6(3):273–5. doi:10.1111/dom.12230.
75. Elashoff M, Matveyenko A, Gier B, Elashoff R, Butler P. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150–6. doi:10.1053/j.gastro.2011.02.018.
76. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12(9):694–9. doi:10.1016/j.cardfail.2006.08.211.
77. Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ Jr, Maher TD, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;100:824–9. doi:10.1016/j.amjcard.2007.05.022.
78. Mussig K, Oncu A, Lindauer P, Heininger A, Aebert H, Unertl K, et al. Effects of intraveneous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol. 2008;102:646–7. doi:10.1016/j.amjcard.2008.06.029.
79. DeSantis A, Nathan DM, Mulder JE. Sodium-glucose co-transporter 2 inhibitors. 2016. https://www.uptodate.com/contents/sodium-glucose-co-transporter-2-inhibitors-for-the-treatment-of-type-2-diabetes-mellitus?source=see_link. Retrieved 1 Nov 2016.
80. Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol. 2011;300(5):R1009–22. doi:10.1152/ajpregu.00809.2010. Retrieved November 1, 2016
81. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al., EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. doi:10.1056/NEJMoa1504720. Retrieved November 17, 2016
82. Zonszein J, Groop PH. Strategies for diabetes management: using newer oral combination therapies early in the disease. Diabetes Ther. 2016;7(4):621–39. doi:10.1007/s13300-016-0208-5. Retrieved November 16, 2016
83. Janssen Research & Development, LLC. CANVAS-CANagliflozin cardiovascular Assessment Study. In: ClinicalTrials.gov[Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01032629?term=Canagliflozin+Cardiovascular+Assessment+Study&rank=1. Accessed 18 Nov 2016. NLM Identifier: NCT01032629.
84. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Eng J Med. 2017. doi:10.1056/NEJMoa1611925.
85. U.S. Food & Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. (2015). http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm. Retrieved 11 Nov 2016.